Skye Bioscience Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
/ 
Frequently asked questions
To buy Skye Bioscience Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Skye Bioscience Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Skye Bioscience Inc. is SKYE:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Skye Bioscience Inc. has its primary listing on NASDAQ. You can trade Skye Bioscience Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Skye Bioscience Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Skye Bioscience Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Skye Bioscience Inc..